About Bioatla (BCAB)
BioAtla, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
- USD1.73
- USD1.79
- USD1.71
- USD11.73
- -29.20%
- --
- 119.07k
- 262.45k
- 86M
- 1.67
- -78.50%
Stock News
2 hours ago
Dow Jones Futures: Market Correction Intensifies, S&P 500 Nears Key Level; Meta AI Push In Focus
Yahoo
2 hours ago
: Fed rate cuts could come sooner than expected, says former Goldman CEO Lloyd Blankfein
MarketWatch
yesterday
The Ratings Game: Could a break-up of Amazon be good for the stock? Analysts weigh in after FTC lawsuit.
MarketWatch
yesterday
Cramer says Amazon and Google stocks are still buys, despite antitrust lawsuits
CNBC
Unlock More Stock Analysis & Reports
Access to easy in-depth stock analysis and reports from Refinitiv with analyst estimates on share price movements.
